Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Increased offer price to $3.65 per share, a $0.55 per share increaseImproved offer unanimously approved by Revance Board of Dir...
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charlesto...
Needham analyst Serge Belanger reiterates Revance Therapeutics (NASDAQ:RVNC) from Hold to Hold.
Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announce...
Barclays analyst Balaji Prasad maintains Revance Therapeutics (NASDAQ:RVNC) with a Equal-Weight and lowers the price target ...
Board of Directors of Revance Recommend Stockholders Tender their SharesJOHNSON CITY, Tenn., Dec. 12, 2024 /PRNewswire/ -- Crow...
Mizuho analyst Vamil Divan maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and lowers the price target from $6.6...
